Ibrance vs Repatha
Side-by-side drug price comparison from Medicare Part D data
Verdict
Repatha costs 93% less per claim than Ibrance ($757.00 vs $10816.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Repatha at $2.6B.
| Metric | Ibrance | Repatha |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $10,816 | $757* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.5B | $2.6B |
| Total Claims | 418,000 | 3,420,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -5.6%* | 24.6% |
| Generic Available | Yes | No |
| Condition | Cancer | High Cholesterol |
| Total Beneficiaries | 36,000 | 398,000 |
Repatha costs 93% less per claim than Ibrance ($757.00 vs $10816.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Repatha at $2.6B.
Explore More
Comparing Ibrance and Repatha on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
Practical use of the comparison: read the data above, then drill into the individual Ibrance and Repatha detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.